MX2022015804A - Agente profilactico o terapeutico para porfiria. - Google Patents

Agente profilactico o terapeutico para porfiria.

Info

Publication number
MX2022015804A
MX2022015804A MX2022015804A MX2022015804A MX2022015804A MX 2022015804 A MX2022015804 A MX 2022015804A MX 2022015804 A MX2022015804 A MX 2022015804A MX 2022015804 A MX2022015804 A MX 2022015804A MX 2022015804 A MX2022015804 A MX 2022015804A
Authority
MX
Mexico
Prior art keywords
porphyria
pyrrolidin
prophylactic
phenyl
therapeutic agent
Prior art date
Application number
MX2022015804A
Other languages
English (en)
Inventor
Fumihiro Takahashi
Tsuyoshi Suzuki
Masahiro Kondo
Akihito Ogasawara
Kazumi Hyoudou
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority claimed from PCT/JP2021/022036 external-priority patent/WO2021251450A1/ja
Publication of MX2022015804A publication Critical patent/MX2022015804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un fármaco para tratar o evitar porfiria, que comprende ácido 1-{2-[(3S,4R)-1-{[(3R,4R)-1-ciclopentil-3-fluoro-4-(4-metoxifenil )pirrolidin-3-il]carbonil}-4-(metoximetil)pirrolidin-3-il]-5-(tri fluorometil)fenil}piperidin-4-carboxílico o una sal o cocristal farmacéuticamente aceptables de éste como un ingrediente activo, en donde la dosis del ácido 1-{2-[(3S,4R)-1-{[(3R,4R)-1-ciclopenti l-3-fluoro-4-(4-metoxifenil)pirrolidin-3-il]carbonil}-4-(metoxime til)pirrolidin-3-il]-5-(trifluorometil)fenil}piperidin-4-carboxíl ico o la sal o cocristal farmacéuticamente aceptables de éste es de 50 a 500 mg/día.
MX2022015804A 2020-06-10 2021-06-10 Agente profilactico o terapeutico para porfiria. MX2022015804A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020100952 2020-06-10
JP2020134451 2020-08-07
PCT/JP2021/022036 WO2021251450A1 (ja) 2020-06-10 2021-06-10 ポルフィリン症の予防又は治療剤

Publications (1)

Publication Number Publication Date
MX2022015804A true MX2022015804A (es) 2023-04-05

Family

ID=78282128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015804A MX2022015804A (es) 2020-06-10 2021-06-10 Agente profilactico o terapeutico para porfiria.

Country Status (10)

Country Link
US (1) US20230248713A1 (es)
EP (1) EP4166140A1 (es)
JP (1) JP6959478B1 (es)
KR (1) KR20230016006A (es)
CN (1) CN115942934A (es)
AU (1) AU2021289913B2 (es)
BR (1) BR112022025099A2 (es)
CA (1) CA3186880A1 (es)
IL (1) IL298952A (es)
MX (1) MX2022015804A (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024029599A1 (ja) * 2022-08-03 2024-02-08 田辺三菱製薬株式会社 １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035074T2 (en) 2006-08-31 2018-05-02 Clinuvel Pharmaceuticals Ltd Alpha-MSH derivatives for the treatment of photodermatoses
CA2950072C (en) 2014-05-29 2019-03-26 Mitsubishi Tanabe Pharma Corporation Novel pyrrolidine compound and application as melanocortin receptor agonist
TWI834791B (zh) 2018-12-28 2024-03-11 日商田邊三菱製藥股份有限公司 吡咯啶化合物的結晶

Also Published As

Publication number Publication date
CA3186880A1 (en) 2021-12-16
KR20230016006A (ko) 2023-01-31
AU2021289913A1 (en) 2023-02-02
US20230248713A1 (en) 2023-08-10
JP6959478B1 (ja) 2021-11-02
AU2021289913B2 (en) 2024-03-28
CN115942934A (zh) 2023-04-07
IL298952A (en) 2023-02-01
JPWO2021251450A1 (es) 2021-12-16
EP4166140A1 (en) 2023-04-19
BR112022025099A2 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
RU2010133241A (ru) Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2023007192A (es) Inhibidores de prmt5.
NZ714963A (en) Compositions and methods for treating anemia
EA023500B1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
TW200639159A (en) Treatment of pain
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
TW200616644A (en) Medicine for prevention or treatment of diabetes
PT1791537E (pt) Derivados de 3-ariltioindole-2-carboxamida e seus análogos como inibidores da cinase da caseína i
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
MX2022015804A (es) Agente profilactico o terapeutico para porfiria.
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MX2023012521A (es) Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas.
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
JP2019512467A (ja) 糖尿病性足感染症の処置のための医薬
NZ597957A (en) Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients
AU2021311245A8 (en) Compound for androgen receptor degradation, and pharmaceutical use thereof